However, in situ, the priming of anti-cancer immunity by APCs may be hampered in HCC, since intra-tumoural activated DCs showed less expression of CD40 when compared to adjacent tissues in the majority of patients, especially in those with tumour suppressor gene mutations (183, 184). The gene discussed is CD40; the disease is hepatocellular carcinoma.